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ABSTRACT
Objective: Dissolution test serves as a quality control tool for assessment of drug release from dosage form as well as a research tool to optimize new 
formulations. The existing guidelines by FDA, EMA, ICH, USP, etc., describe specifications for the dissolution of immediate release as well as modified 
release oral dosage form. However, none of them have discussed about the discriminatory potential of the medium to differentiate release profile of two 
or more products that are pharmaceutically equivalent. It is pertinent to add here that the pharmaceutical equivalents are not always bioequivalent. 
Hence, a discriminatory dissolution procedure is a must requirement to differentiate the release behavior of drug from a pharmaceutically equivalent 
product that contains different types and amount of excipient in the formulation. This also becomes more cumbersome when it is desirable for 
prediction of in vivo behavior of a drug when it is converted into a novel delivery system like nanoparticles. The reason could be the presence of 
excipients used to formulate drug nanoparticles into solid oral dosage form, may change the drug disintegration as well as dissolution behavior, which 
ultimately may lead to altered bioavailability.
Methods: In this study, the nanoparticles of meloxicam were prepared using wet media milling and the milled samples were dried using spray drier. 
The dried nanoparticles were converted into tablet dosage form by varying the type of diluent. To one batch lactose was used and another one was 
containing dicalcium phosphate (DCP). The assessment of release of meloxicam from these two batches was evaluated in various dissolution media.
Results: The study revealed that in all the cases the nanoparticulate tablets of Batch 1 have given increased dissolution profile as compared to 
marketed formulation (Muvera®), Batch 2 and controlled tablets of meloxicam. This proved that the excipients also play a major role in the release 
behavior of drug otherwise if it was not so, the nanoparticulate tablets of Batch 1 and Batch 2 would have given the same dissolution profile in all the 
tried media. Batch 1 containing lactose with a higher surface area provided more and rapid wetting of the drug by the dissolution media compared to 
Batch 2 that contained DCP as a major diluent.
Conclusion: Among all the dissolution media tried to evaluate the discriminatory power and simulation with a biorelevant medium, the biphasic 
medium of pH 1.8, 4.8 and 6.8 has promised to simulate with biorelevant media. However, the medium of pH 6.8 has shown the best dissolution profile.
Keywords: Solubility, Compendial media, Biphasic media, Dissolution, Meloxicam.
INTRODUCTION
Meloxicam is an antirheumatoid drug which falls in the category of 
non-steroidal anti-inflammatory drugs. “Previous studies on meloxicam 
pharmacokinetics shown that after oral administration, it has slow 
absorption with Tmax that is longer than 5 hrs [1-5]. In comparison, 
intramuscular injection of meloxicam reached the maximum plasma 
concentration (Cmax) within 1.5 hrs of administration and 90% of the Cmax 
within 30-50 minutes over the dose range of 5-30 mg in humans [6,7]. 
Hence, intramuscular administration of meloxicam could shorten the onset 
of action since rapid pain relief is required in the case of acute and painful 
exacerbations of rheumatoid arthritis. However, due to the potential local 
tissue irritation and necrosis, intramuscular administration of meloxicam 
is not recommended for the chronic use and should be switched to oral 
formulation as soon as the rapid onset of action is achieved [7]. Hence, 
the development of an oral formulation of meloxicam with faster onset 
of action while maintaining the prolonged exposure could be a very good 
alternative.” It belongs to BCS Class II and possesses poor solubility and 
thereby dissolution rate limited oral bioavailability. The details about 
physicochemical properties of meloxicam are shown in Table 1.
In last one decade, various approaches have been reported to improve 
the dissolution rate of meloxicam. Some of them include solubilization 
in surfactant solutions, the use of cosolvents, pH adjusted solutions, 
emulsions, liposomes, complexation with cyclodextrins, and solid 
dispersions [10-16].
However, above-mentioned techniques have some or the other 
limitations, like difficulty to scale up, clinical toxicity or stability, etc.
Nanosuspensions, on the other hand, have proven to be the cornerstone 
approach to overcome dissolution rate limited bioavailability of poorly 
soluble drugs [17].
There are several reports to overcome stability related problems, 
wherein nanosuspension have been prepared and been successful to 
get marketed [18]. Despite this the physiochemical stability related 
challenges such as sediments and Ostwald’s ripening cannot be 
ignored. To overcome such problems, solidification of nanosuspensions 
through spray drying or lyophilization and the conversion into tablets, 
or capsules is now greatly practiced. Among, various oral dosage form 
systems, tablets are considered as the most common and convenient 
route due to their acceptable patient compliance, exposure of drugs 
to large surface area, rich blood supply, prolonged drug retention, 
advantage of scale up, and commercialization [18].
Dissolution test is utilized as either a research tool for optimizing new 
formulations or a quality control test to monitor the uniformity and 
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reproducibility of production batches. In biological systems, drug 
dissolution is an important attribute before systemic absorption [19]. 
The dissolution test also reflects significant differences in bioavailability 
arising from differences in dissolution [20] and discriminate formulation 
factors such as polymers, particle surface area, and physical and chemical 
characteristics of the drug [21,22]. When dissolution testing is used to 
forecast the in vivo performance of a drug, it is critical that the in vitro test 
should mimic the in vivo conditions as closely as possible. The nature of 
the dissolution medium affects the dissolution rate [23,24]. It is pertinent 
to add here that a medium that could be able to discriminate the release 
behavior of drug, either in its conventional or novel form due to the type 
of excipients used in the formulation could help the formulation scientists 
to overcome the challenges related to batch to batch variations as well as 
quality of dosage form prepared, which are pharmaceutically equivalent. 
Such attempts could also provide some regulatory considerations related 
to bioequivalence studies of products. In the present study was aimed to 




Meloxicam was procured from Jackson Pharmaceuticals, Amritsar, 
India. Marketed formulation of meloxicam “Muvera®” was purchased 
from local chemist. Phospholipid (Egg lecithin) was gifted by Lipoid, 
Germany. Sodium lauryl sulfate (SLS) and hydroxypropyl methyl cellulose 
(HPMC) were purchased from Loba Chemie, India. Lactose monohydrate, 
dicalcium phosphate (DCP) and magnesium stearate were purchased from 
Qualikems fine chemical Pvt. Ltd., India. Sodium dihydrogen phosphate, 
potassium dihydrogen orthophosphate, boric acid, sodium hydroxide, 
sodium chloride, microcrystalline cellulose, octanol, and tritonX100 were 
purchased from Central Drug laboratories, India. Sodium taurocholate 
was purchased from Sigma-Aldrich life sciences, India. Crosspovidone 
(Kollidon CL) was purchased from BASF, India. Milk was purchased from 
Heritage, India. Triple distilled water was used throughout the study.
Preparation of nanosuspension
The nanosuspension of meloxicam was prepared by the method 
reported in our recent published work [25]. The known amount of 
meloxicam was first dispersed in the dispersion medium containing 
known amount of HPMC and SLS and mixed in a mechanical mixer 
at 500 rpm. Afterward the suspension was milled using bead mill 
(Model: Lab Star 1, Netzsch Mill, Germany) for particle size reduction. 
Prepared nanosuspension was dried using spray drier (Spray Mate, Jay 
Instruments Pvt. Ltd. India). A batch of 250 g meloxicam nanosuspension 
was poured in spray dryer to make it into fine drug nanoparticles. Dried 
nanoparticles were collected at the end of the cyclone separator.
Characterization of nanosuspension
Prepared nanosuspension was characterized for particle size, zeta 
potential, % drug loading, and stability as per the procedure discussed 
in our previous report [25]
Compression of nanoparticles and pure drug to tablet dosage form
Spray dried nanoparticles were converted into tablets by varying the 
type of diluents. Batch 1 was containing lactose monohydrate as diluent, 
whereas Batch 2 was containing DCP as diluent (Table 2). Lactose is 
water soluble excipient, forms more microcavities in the polymer in 
polymer matrices. Hence, help in better swelling and disintegration 
and dissolution. Whereas DCP is water-insoluble excipient which 
causes less prominent swelling, erosion, and drug release sustaining 
properties in matrices. On the other hand, DCP provides a better 
compaction as that of lactose [26]. Hence, the impact of this excipient 
in release of meloxicam nanoparticles in various pH dependent media 
is worth exploring.
To compare their dissolution profile with micronized form of meloxicam, 
a controlled batch was also prepared, wherein unmilled meloxicam was 
kept as API.
All of the materials were passed through sieve No. 60 before use and the 
accurately weighed amounts of ingredients were thoroughly mixed and 
compressed into 100 mg tablets using multi punch machine (Trover 
Pharm, India) of 8 mm flat punch and die set.
In vitro disintegration time
The disintegration test has been carried out for prepared tablets 
(Batches 1 and 2), Muvera® (marketed formulation of meloxicam) and 






Solubility in water 7.15 mg/L (0.154 mg/mL)
Solubility in different pH 
based aqueous buffers
Meloxicam has pH dependent solubility. 
It is an example of acidic NSAID. The 
aqueous solubility of acidic NSAIDs is 
pH dependent. Decrease in pH leads to 
an increase in the ratio of non-ionized 
to ionized drug, combined with 
decrease in solubility with decreasing 
pH and vice versa with increase in pH




pKa (Strongest acidic) 4.47
pKa (Strongest basic) 0.47
NSAIDs: Non-steroidal anti-inflammatory drugs
























Batch 1 11.55 (containing 
meloxicam equvalent 
to 7.5 mg)
66.52 - 16.63 3.8 0.5 1
Batch 2 11.55 (containing 
meloxicam equvalent 
to 7.5 mg)
- 66.52 16.63 3.8 0.5 1
Control 
Batch 3
7.5 68 - 18 5 0.5 1
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controlled Batch in different media which were used for dissolution 
studies.
The test was carried out on six tablets using tablet disintegration 
tester (DT1000, Lab India). For the study, 900 ml of phosphate buffer 
of pH 6.8 was used. The temperature of the medium was maintained at 
37°C±0.5°C. “The time taken for complete disintegration of the tablet 
with no palpable mass remaining in the apparatus was measured in 
seconds” [27].
In vitro dissolution studies
The dissolution study was performed for Batches 1 and 2 containing 
meloxicam nanoparticles (equivalent to 7.5 mg), marketed formulation 
(Muvera®), and controlled batch, in dissolution tester USP II apparatus 
(DS8000, LAB INDIA). The study was conducted in three different types 
of media, which includes, Compendial pH buffer media, biorelevant 
media and biphasic media at temperature 37°C±0.5°C and 50 rpm 
agitation speed.
At specified time intervals of 5, 10, 15, 20, 30, 45, 60, 75 and 90 minutes, 
“5 ml of dissolution medium was withdrawn and replaced with an equal 
volume of medium to maintain a constant total volume” [28]. Samples 
were filtered through a 0.45 µm membrane filter, and the samples were 
analyzed at 359 nm using UV-visible spectrophotometer (UV-1800, 
Shimadzu, Japan).
Composition of dissolution media
All the compendial buffers were prepared as per USP 31 NF 27 [29]. The 
composition of different dissolution media are as follows:
HCL (0.2 N) buffer solution of pH 1.8
Potassium chloride (3.7 g) and concentrated hydrochloric acid (7 ml) 
were added to 1000 ml volumetric flask and volume was made up to 
1000 ml using distilled water. The pH of the buffer was adjusted to 
1.8 using 0.1 N HCL or 0.1 N NaOH. Phthalate (0.2 N) buffer solution 
of pH 4.8.
Potassium hydrogen phthalate (10.4 g) and NaOH (6.6 g) were added 
to 1000 ml volumetric flask and volume was made up to 1000 ml using 
distilled water. The pH of solution was adjusted to 4.8.
Phthalate buffer (0.2 N) solution of pH 5.6
Potassium hydrogen phthalate (10.4 g) and NaOH (7.1 g) were added 
to 1000 ml volumetric flask and volume was made up using distilled 
water. The pH of solution was adjusted to 5.6.
Phosphate buffer (0.2 N) solution of pH 6.8
Potassium dihydrogen orthophosphate (6.8 g) and NaOH (9.0 g) were 
added to 1000 ml volumetric flask and volume was made up to 1000 ml 
using distilled water. The pH of solution was adjusted to 6.8.
Phosphate buffer (0.2 N) solution of pH 7.4
Potassium dihydrogen orthophosphate (6.8 g) and NaOH (16.9 g) were 
added to 1000 ml volumetric flask and volume was made up using 
distilled water. The pH of solution was adjusted to 7.4.
Borate buffer (0.2 N) solution of pH 9.6
Boric acid (3.1 g), 3.7 g of potassium chloride, and 14.7 g of NaOH were 
added to 1000 ml volumetric flask and volume was made up using 
distilled water. Solution pH was adjusted to 9.6.
Fasted state simulated gastric fluid (FaSSGF) [29-35]
This media was prepared mixing 2 g of sodium chloride, 3 g 
of hydrochloric acid, 1 g of tritonX 100-1000 ml volumetric 
flask and volume was made up using distilled water. The pH of 
solution was adjusted to 1.8. The composition of FaSSGF is shown in 
Table 3.
Fasted state simulated intestinal fluid (FaSSIF) [29-35]
This medium was prepared in two steps, wherein first step 
describes about the preparation of blank FaSSIF and the second 
step describes the preparation of standard solution of FaSSIF. Blank 
was prepared by adding 3.48 g sodium dihydrogen orthophosphate, 
6.1 g of sodium chloride, 0.34 g of sodium hydroxide to 1000 mL 
volumetric flask and volume was made up using distilled water. Final 
FaSSIF was prepared by adding 1.65 g of sodium taurocholate and 
0.519 g of lecithin to 1000 ml volumetric flask and volume was made up 
using blank FaSSIF. pH of solution was adjusted to 6.5. The composition 
of blank FaSSIF and FaSSIF is shown in Tables 4 and 5.
Fed state simulated intestinal fluid (FeSSIF) [29-35]
This medium was prepared in two steps, wherein first step describes 
about the preparation of blank FeSSIF and the second step describes the 
preparation of standard solution of FeSSIF. Blank FeSSIF was prepared 
by adding 8.65 g of glacial acetic acid, 11.87 g of sodium chloride, 4.04 g 
of sodium hydroxide to 1000 ml volumetric flask and volume was made 
up using distilled water. The final solution was prepared by adding 






Distilled water qs 1 L
qs: Quantity sufficient
Table 4: Composition of blank fasted state simulated intestinal 
fluid [29‑35]
Material Quantity (g)
Sodium dihydrogen orthophosphate 3.40
Sodium chloride 6.20
Sodium hydroxide 0.34
Distilled water qs 1 L
qs: Quantity sufficient




Blank FaSSIF qs 1 L
qs: Quantity sufficient, FaSSIF: Fasted state simulated intestinal fluid
Table 6: Composition of blank FeSSIF [35]
Material Quantity (g)
Glacial acetic acid 8.65
Sodium chloride 11.87
Sodium hydroxide 4.04
Distilled water qs 1 L
qs: Quantity sufficient, FeSSIF: Fed state simulated intestinal fluid




Blank FeSSIF qs 1 L
qs: Quantity sufficient, FeSSIF: Fed state simulated intestinal fluid
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8.25 g of sodium taurocholate, 2.96 g of lecithin to 1000 mL volumetric 
flask and volume was made up using blank FeSSIF. pH of solution was 
adjusted to 5.0. The composition of blank FeSSIF and FeSSIF is shown 
in Tables 6 and 7.
Biphasic dissolution medium
This media contains two phases; organic phase and an aqueous phase. 
Octanol was taken as organic phase and buffer solution was taken as 
the aqueous phase. The biphasic media of different pH 1.8, 4.8, 6.8, 7.4 
were prepared by adding 100 ml of octanol to 800 ml of aqueous buffer, 
whose preparation was discussed in previous sections.
Composition of milk medium
Simulated gastric fluid (SGF) medium containing milk was prepared 
using equal parts of milk and SGF pH 1.2. The final pH was taken 
to 3.0 with either 0.1 M HCl or 0.1 M NaOH. The SGF composition 
was already discussed in earlier section. Different milk media were 
prepared which are (a) whole fat milk 50%, (b) semi skimmed milk, 
and (c) skimmed milk.
Statistical analysis of data
The in vitro release profiles of meloxicam nanosuspension were 
compared using model independent analysis for calculation of 












   = + − ×     
∑
Here, n indicates number of time points at which % drug dissolved was 
determined, Rt is the % drug dissolved of one formulation at a given 
time point and T indicates the % drug dissolved of the formulation to be 
compared at the same time point [37,38].
RESULTS AND DISCUSSION
Characterization of meloxicam nanoparticles [25]
Mean particle size distribution d (50) of prepared nanoparticles of 
meloxicam was found to be 265 nm with 65.21% drug loading and zeta 
potential of −25.26 mV. The dissolution profile of fresh nanosuspension 
and aged nanosuspension (Kept for stability studies) showed that the 
aged nanosuspension appeared to have lower dissolution rate than the 
fresh nanosuspension in the graph; however, a similarity factor (F2) of 
53.25 indicated that the two release profiles were acceptably similar [25].
Solubility studies of prepared nanoparticles and API in different 
dissolution media
Table 8 represents the saturation solubility of meloxicam 
nanoparticles and pure API in in 250 mL of media, respectively, in 
different dissolution media, which includes, compendial pH 1.8, 
4.8, 5.6, 6.8, 7.4, 9.6, FaSSGF, FaSSIF, FeSSIF, biphasic media of 
pH 1.8, 4.8, 6.8, 7.4. Pure meloxicam showed maximum solubility 
of 4.147±0.95 µg/ml in the biphasic medium at pH 7.4. Meloxicam 
nanoparticles have showed a profound increase in solubility, with a 
maximum solubility of 46.82±0.23 µg/ml in the biphasic medium at 
pH 7.4 with a value of Cs/Cd 4.071. A value above 3 represents a very 
Table 8: Saturation solubility (mean±SD) of meloxicam API and nanoparticles in different dissolution media
Dissolution media Mean±SD (n=3*)
Pure API (amount 















pH buffer 1.8 0.001±0.0001 - 0.002±0.001 8.43±0.18 0.73±0.06 16.86±1.18
pH buffer 4.8 0.004±0.002 - 0.008±0.003 11.26±0.56 0.98±0.67 22.52±1.24
pH buffer 5.6 0.16±0.004 0.014±0.001 0.32±0.011 14.94±1.44 1.30±0.93 29.88±2.11
pH buffer 6.8 0.03±0.005 0.002±0.001 0.06±0.024 26.71±1.05 2.32±0.17 53.42±2.73
pH buffer 7.4 0.05±0.008 0.004±0.001 0.10±0.004 37.93±1.34 3.30±0.72 75.86±3.16
pH buffer 9.6 0.28±0.002 0.025±0.002 0.51±0.05 44.02±2.19 3.83±0.43 88.40±2.17
FaSSGF 0.76±0.014 0.07±0.006 1.53±0.21 12.36±0.35 1.07±0.32 24.72±1.94
FaSSIF 1.21±0.003 0.11±0.018 2.43±0.19 28.64±0.83 2.50±0.76 57.28±1.11
FeSSIF 0.97±0.013 0.08±0.009 1.94±0.32 19.27±1.93 1.68±0.22 38.54±0.87
Biphasic media pH 1.8 2.46±0.026 0.21±0.023 4.93±0.22 29.69±2.85 2.58±0.71 59.38±1.45
Biphasic media pH 4.8 2.63±0.018 0.23±0.013 5.27±0.48 38.30±1.91 3.33±0.88 76.60±1.92
Biphasic media pH 6.8 3.81±0.014 0.33±0.009 7.62±0.32 43.17±1.02 3.75±0.72 86.34±0.93
Biphasic media pH 7.4 4.15±0.95 0.36±0.010 8.29±0.92 46.82±0.23 4.07±1.14 93.64±2.12
n=3*: Number of replicates of study=3. FaSSGF: Fasted state simulated gastric fluid, FaSSIF: Fasted state simulated intestinal fluid, FeSSIF: Fed state simulated intestinal 
fluid, SD: Standard deviation
Table 9: Disintegration results (mean±SD) for prepared tablets
Media used Mean±SD (n=3*)
Marketed (Muvera®) (min) Batch 1 (min) Batch 2 (min) Controlled batch (Batch 3) (min)
Buffer pH 1.8 2.36±0.21 0.41±0.04 0.27±0.021 2.24±048
Buffer pH 4.8 2.17±0.41 0.47±0.08 0.28±0.019 2.21±0.23
Buffer pH 5.6 2.25±0.89 0.45±0.10 0.21±0.054 2.16±0.16
Buffer pH 6.8 2.11±1.12 0.37±0.09 0.31±0.029 2.27±0.37
Buffer pH 7.4 2.17±0.98 0.39±0.12 0.29±0.087 2.28±0.98
Buffer pH 9.6 1.58±0.21 0.34±0.076 0.28±0.042 2.26±0.016
FaSGF – 1.8 2.34±0.32 0.42±0.052 0.30±0.066 2.20±0.32
Fassif – 6.5 2.13±0.24 0.36±0.018 0.32±0.042 2.34±0.65
FeSSIF – 5.0 2.56±0.34 0.45±0.022 0.35±0.078 2.37±0.31
Biphasic media pH 1.8 2.35±1.12 0.41±0.067 0.27±0.092 2.21±0.39
Biphasic media pH 4.8 2.17±0.21 0.45±0.054 0.28±0.040 2.26±0.48
Biphasic media pH 6.8 2.24±0.37 0.32±0.087 0.27±0.034 2.27±0.64
Biphasic media pH 7.4 2.12±0.65 0.35±0.076 0.31±0.028 2.28±0.27
n=3* : Number of replicates of study=3. FaSSGF: Fasted state simulated gastric fluid, FaSSIF: Fasted state simulated intestinal fluid, FeSSIF: Fed state simulated intestinal 
fluid, SD: Standard deviation
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good sink condition [39]. This may be due to increase in surface area 
and wettability.
In vitro disintegration time
Nanoparticulated tablets showed less disintegration time when 
compared to marketed and controlled. However, all the tablets have 
passed pharmacopoeial limits (less than 5 minutes). The results are 
shown in Table 9.
In vitro dissolution testing
Dissolution in compendial medium
To evaluate the discriminatory power and drug release potential, the 
dissolution studies were carried out in conventional media of pH 1.8, 
4.8, 5.6, 6.8, 7.4 and 9.6 buffers, respectively, using the marketed 
formulation (Muvera®), controlled formulation, Batches 1 and 2 of 
nanoparticulated meloxicam tablets.
In Fig. 1, it was observed that the Batch 2 and controlled batch have 
given a poor drug release as compared to Batch 1 and Muvera®. This 
clearly shows that the effect of DCP on drug release of Batch 2 and 
lactose monohydrate on drug release of Batch 1. The decrease in drug 
release profile of Batch 2 was mainly due to the presence of DCP that 
forms stagnant layer over the meloxicam nanoparticles, and thus, 
the dissolution medium could not sufficiently wet the meloxicam 
nanoparticles. However, in Batch 1, lactose monohydrate which was 
almost amorphous in nature and has larger surface area provided 
immediate wetting to the meloxicam nanoparticles after disintegration, 
and thus, enhanced its drug release.
It was observed that no sufficient sink conditions have been achieved 
with any of the formulations at pH 1.8. The maximum drug release 
found with Batch 1 was 12.45%, Batch 2 with 6.72%, Muvera® with 
9.63%, and controlled batch with 3.9%, respectively, in 75 minutes, 
which was much lesser as far as the limit of quantification is 
concerned for an immediate release dosage form (i.e., 75% in 
15 minutes) [28].
Another experiment carried out at pH 4.8 and 5.6 buffer also showed the 
same results with little increase in dissolution profile (i.e., Batch 1 with 
42.7%, Batch 2 with 10.51%, Muvera® with 46.5%, and controlled batch 
with 6% at pH 5.6). The results are shown in Fig. 2 and Batch 1 with 
52.4%, Batch 2 with 14.6%, Muvera® with 46.4%, and controlled with 6% 
at pH 4.8 as shown in Fig. 3. This revealed that at pH 4.8 four folds increase 
in dissolution profile was observed with Batch 1, two folds with Batch 2, 
Fig. 1: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in compendial pH buffer 1.8
Fig. 2: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in compendial pH buffer 5.6
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five folds increase with Muvera®, and two folds increase with controlled 
batch as compared to drug release at pH 1.8. At pH 5.6, four folds increase 
in drug release was found with Batch 1, 1.5 folds increase with Batch 2, 
four folds increase with Muvera® and two folds increase with controlled 
batch as compared to pH 1.8. However, the drug release was still not 
achieved with this dissolution media as per compendial requirements.
From Fig. 4, revealed 68.4 % drug release with Batch 1, 35.8% with 
Batch 2, 62.9% with Muvera®, and 37.2% with controlled at pH 6.8. 
This showed that a 5.5 folds increase in drug release with Batch 1, 8.5 
folds increase with Batch 2, 7 folds increase with Muvera®, and 12 folds 
increase with controlled as compared to pH 1.8. Fig. 5 shows the drug 
release in pH 7.4, as Muvera® with 64 %, Batch 1 with 65.7%, Batch 2 with 
45%, and Controlled batch with 39.31%. However, still the compendial 
requirements have not been achieved. When dissolution studies were 
carried out at pH 9.6, 71.3% drug release was observed with Batch 1, 
68.1% drug release with Batch 2, 68.79% with Muvera® and 68.13 % 
with controlled one (Fig. 6). Here, six folds increase was observed with 
Batch 1, 5.5 folds increase with Batch 2, 5.5 folds increase with Muvera® 
and 24 folds increase controlled batch as compared to pH 1.8. In this case, 
Batch 1 has fulfilled compendial requirements; however, still the other 
formulations have not shown a proper drug release as per compendial 
requirements. This proved that the drug is not only having pH dependent 
solubility profile but it is also considered as poorly soluble drug because 
even 900 ml of dissolution media at pH 9.6 has not shown 100% drug 
release in 75 minutes and thus no proper sink conditions has been 
achieved for meloxicam. The US-FDA guideline do not allow the use of 
pH 9.6 buffer for routine quality control analysis of drug because they 
are not considered as physiologically relevant medium (i.e. not in range 
of 1.8-7.5). Furthermore, pH above 8.0 causes column degradation 
since nowadays most of the dissolution apparatus are coupled with 
autosampler high performance liquid chromatography [40].
All these problems proved that the normal compendial media cannot 
surrogate the in vivo performance of meloxicam. Hence, it warranted 
to develop a medium which should be rich with phospholipids and bile 
salts to mimic the in vivo physiological conditions. Hence, an attempt has 
been made to use biorelevant media to evaluate the drug release profile 
of above said four formulations. In view of this, six different biorelevant 
media have been prepared which are FaSSGF (pH 1.8), FaSSIF (pH 6.5), 
FeSSIF (pH 5.0), SGF containing whole fat milk (pH 3.0), SGF containing 
semi-skimmed milk (pH 3.0), and SGF containing skimmed milk 
(pH 3.0). The compositions of these media are already discussed above.
The dissolution studies carried out in FaSSGF (pH 1.8) (Fig. 7) 
showed that 57.41% drug release from Batch 1, 47.5% drug release 
Fig. 3: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in compendial pH buffer 4.8
Fig. 4: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in compendial pH buffer 6.8
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from Batch 2, 16.8% from Muvera® and 13.4 % from controlled 
Batch in 75 minutes. Almost the same results were obtained when 
studies were carried out in FeSSIF (pH 5.0) for all formulations 
(Fig. 8). In this case also, the Batch 2 has shown a poor drug release 
profile that may be because of the presence of DCP. However, the 
dissolution study in FaSSIF (pH 6.5) has shown a drastic change in 
drug release of Batch 1, 70.3% drug release of Batch 2, 88.0% drug 
release of Muvera® and 27% drug release of controlled in 75 minutes 
(Fig. 9).
As it is a well-known fact that bio relevant media are considered the 
most predictive media for in vitro in vivo correlation (IVIVC) studies 
during drug development studies that simulate gastrointestinal fluid 
more accurately [40]. Therefore, it can be considered that the results 
obtained by carrying out dissolution studies in FaSSGF (pH 1.8), FaSSIF 
(pH 6.5), and FaSSIF (pH 5.0) will be the surrogate marker for meloxicam 
nanoparticulated tablet performance inside the body. Thus, the results 
shown by FaSSGF (pH 1.8) revealed that meloxicam is a pH dependent 
poorly soluble drug and is a weak acid. Moreover, the results observed 
with FeSSIF (pH 5.0) showed that food is having a drastic effect on drug 
release of meloxicam nanoparticles as shown in Fig. 8. The drug release 
in FeSSIF pH 5.0 is almost 50% to that of FaSSIF (pH 6.5). Thus, it can 
be considered that presence of food may cause dissolution limited 
absorption of meloxicam nanoparticles from its tablet dosage form 
and thereby decrease in the therapeutic potential of meloxicam. Hence, 
FaSSIF (pH 6.5) could be used for IVIVC of meloxicam nanoparticles 
when human volunteers/animals are in fasting conditions and FeSSIF 
(pH 5.0) when human volunteers/animals are in fed state. “However, 
these media look good when normal research and development is 
concerned but due to their complex composition, availability of costly 
surfactants (sodium taurocholate and egg lecithin) and questionable 
storage stability, these media are expensive and their use is limited as 
a regular quality control medium”[35,39]. For example, 1 L of FeSSIF 
can cost as much as the US $ 700 [39]. This warrants to develop a single 
dissolution test medium which can work almost like biorelevant media 
during the early phase drug development process as well as for regular 
quality control purpose. “The replacement of natural bile components 
(sodium taurocholate and lecithin) with different simple testing media 
like milk and biphasic media may be the alternative approach for this 
issue” [41].
Fig. 5: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in compendial pH buffer 7.4
Fig. 6: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in compendial pH buffer 9.6
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Fig. 7: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in fasted state simulated gastric fluid
Fig. 8: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in fed state simulated intestinal fluid
Fig. 9: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in fasted state simulated intestinal fluid
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Fig. 10: Dissolution profile of Batch 1 and Batch 2 in skimmed, Semi skimmed and whole fat milk
Fig. 11: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in biphasic media of pH 1.8
Milk as dissolution medium
An attempt has been taken by preparing SGF containing 50% milk 
(whole fat), SGF containing semi skimmed milk or skimmed milk. The 
pH of each medium was adjusted to 3 as shown in Fig. 10. For Batch 1, 
45.20% drug release was observed with skimmed milk, 55.62% drug 
release with semi-skimmed milk and 65.36% drug release with whole 
fat milk, respectively, in 75 minutes, whereas 38.39% drug release for 
Batch 2 in skimmed milk, 40.20% drug release in semi skimmed milk, 
and 48.32% drug release with whole fat milk in 75 minutes, respectively.
The results showed that as the fat content was increasing in the media; 
the dissolution rate of meloxicam nanoparticles was increasing for both 
batches. Thus, it provides a clear evidence of an increase in dissolution 
rate of meloxicam nanoparticles tablets in milk containing media. Since, 
meloxicam is a lipophilic drug (BCS class II), the increased fat content of 
milk would be expected to aid solubility and thereby dissolution rate of 
the drug. However, these milk containing media also do not provide the 
drug release of meloxicam nanoparticulate tablets as per compendial 
requirements. Hence, our research has been moved toward the use of 
biphasic dissolution media.
Biphasic medium
The potential of the biphasic media using n-octanol has been reported by 
Heigoldt et al. [41] for predicting in vivo performance of Investigational 
New Drug BIMT 17. Hence, we have tried to explore the potential of 
biphasic dissolution media for providing a similar dissolution profile 
as that of FeSSIF (pH 5.0) and FaSSIF (pH 6.5). The choice of n-octanol 
as the organic phase in the biphasic system described in this report 
was based on its advantageous physical/chemical properties [42,43], 
like: (1) n-octanol is practically insoluble in water (0.05 g/100 g H2O); 
(2) n-octanol is less dense than water (specific gravity 0.825 at 20°C), 
permitting ease of sampling; (3) n-octanol possesses low volatility 
(b.p.=195°C) hence, n-octanol will not readily evaporate at 37°C, and 
thus, a relatively constant upper phase can be maintained; (4) n-octanol 
possesses rather low viscosity, enabling sampling via conventional 
tubing and pump; (5) meloxicam used in this study, is readily soluble 
in n-octanol and possess octanol/water distribution coefficients with 
log P>3.43 (Table 1), guaranteeing sink conditions in the n-octanol 
layer. By this means, dissolved drug was distributed to the organic layer, 
removed from the aqueous dissolution medium, and a quasi-sink was 
obtained throughout the experiment [41].
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Fig. 12: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in biphasic media of pH 4.8
Fig. 13: Dissolution profile of Muvera®, Batch 1, Batch 2, and controlled batch (Batch 3) in biphasic media of pH 6.8
Fig. 14: Dissolution profile of Muvera®, Batch 1, Batch 2 and controlled batch (Batch 3) in biphasic media of pH 7.4
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In view of this, dissolution profiles of biphasic media at different pH 1.8, 
4.8, 6.8 and 7.4 (Figs. 11-14) were compared with FaSSIF and FeSSIF 
statistically using model independent method (Similarity factor F2). It 
was found that Batch 1 was giving similarity factor of 59.94 between 
FaSSIF and biphasic (pH 6.8) media and 51.71 between FeSSIF and 
biphasic 1.8 media, respectively. On the other hand, similarity factor 
for Batch 2 was calculated and found to be 56.28 between FeSSIF 
(pH 5.0) and bipahsic pH 1.8, and 51.37 between FaSSIF (pH 6.5) and 
biphasic (pH 4.8) media. This revealed that biphasic media of pH 1.8, 
4.8 and 6.8 can be used as a surrogate marker for replacing biorelevant 
media. However, the medium of pH 6.8 has shown the best dissolution 
profile. Hence, during drug development studies, instead of using 
costly biorelevant media, it is better to use a simple biphasic medium 
which simulates in vivo conditions and helps in predicting in vivo drug 
performance of meloxicam nanoparticulate tablets.
CONCLUSION
In this study, the nanoparticles of meloxicam were prepared using wet 
media milling and the milled samples were dried using spray drier. 
The dried nanoparticles were converted into tablet dosage form by 
varying the type of diluent. The study revealed that in all the cases the 
nanoparticulate tablets of Batch 1 have given increased dissolution 
profile as compared to marketed formulation (Muvera®), Batch 2 and 
controlled tablets of meloxicam. This proved that the excipients also 
play a major role in the release behavior of drug otherwise if it was 
not so, the nanoparticulate tablets of Batches 1 and 2 would have given 
the same dissolution profile in all the tried media. Batch 1 containing 
lactose with higher surface area provided more and rapid wetting of the 
drug by the dissolution media compared to Batch 2 that contained DCP 
as a major diluent. Among all the dissolution media tried to evaluate 
the discriminatory power and simulation with biorelevant medium, 
biphasic medium of pH 1.8, 4.8 and 6.8 have promised to simulate with 
biorelevant media. However, the medium of pH 6.8 has shown the best 
dissolution profile. In future, in vivo pharmacokinetic study is required 
using a suitable animal to confirm the correlation of in vitro study with 
in vivo milieu.
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